Prognostic Factors and the Significance of Treatment After Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer

Shimada, Yoshihisa; Saji, Hisashi; Yoshida, Kôichi; Kakihana, Masatoshi; Honda, Hiroaki; Nomura, Masatoshi; Usuda, Jitsuo; Kajiwara, Naohiro; Ohira, Tetsuya; Ikeda, Norihiko

doi:10.1378/chest.12-1717

Cited by 61 publications

(74 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated the outcomes and predictive factors for the post-recurrence survival in resected NSCLC patients [3][4][5][6][7][8][9]. However, few reports have so far evaluated the treatment or outcomes of elderly patients.…”

Section: Discussionmentioning

confidence: 99%

“…As non-small cell lung cancer (NSCLC) is a common disease in the elderly population, the number of cases of NSCLC is increasing, with patients older than 80 years of age accounting for 14 % of all patients with lung cancer [2]. Although surgery is the best therapeutic modality for patients with early stages of NSCLC, recurrence has been reported to occur in 20-50 % of all cases [3][4][5][6][7][8][9]. According to the Japanese Lung Cancer Registry Study, tumor recurrence remains a major cause of postoperative death [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The prognosis of patients with recurrence following complete surgical resection of NSCLC is considered to be a multifactorial process, which depends on clinicopathological, biological and treatment characteristics (18). The reported recurrence rates following complete NSCLC resection are 30-75% (6,7,8,9,19,20), and ~15% for pathological stage I cases (21,22). The late recurrence of lung cancer has become an increasing subject of research, due to the high level of curability and the likelihood of long-survival (23).…”

Section: Isolated Brain Metastasis As a Late Recurrence Of Completelymentioning

confidence: 99%

Isolated brain metastasis as a late recurrence of completely resected non-small cell lung cancer

Han

2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The brain is one of the most common sites for non-small cell lung cancer (NSCLC) metastasis; however, late isolated brain metastasis as a recurrence of NSCLC is rare. The present study describes a case of isolated solitary brain metastasis as a late recurrence of NSCLC, which occurred >2 years following the successful resection of the primary tumor, and was identified by magnetic resonance imaging. To the best of our knowledge, this is the first report of isolated brain metastasis as a postoperative recurrence of NSCLC. The aim of the present study was to highlight that, despite its rarity, such recurrence should be considered possible, and particular attention to the treatment of such patients should be paid.

show abstract

“…Other studies were excluded because they did not report the results by stage at the level of granularity needed [26][27][28][29]. The risk of death after experiencing a cancer recurrence was pooled from two studies [30,31].…”

Section: Literature-derived Inputsmentioning

confidence: 99%

“…Death after recurrence Probability of NSCLC-related death within 2 years after a cancer recurrence [30,31] 72.6% 95% CI, 68.9%-76.3% Beta…”

Section: Nsclc-related Mortality and Myplan Costmentioning

confidence: 99%

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

Background. A prognostic test was developed to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC) adenocarcinomas.The objective of this study was to compare the cost-utility of the prognostic test to the current standard of care (SoC) in patients with early-stage NSCLC. Materials and Methods. Lifetime costs (2014 U.S. dollars) and effectiveness (quality-adjusted life-years [QALYs]) of ACT treatment decisions were examined using a Markov microsimulation model from a U.S. third-party payer perspective. Cancer stage distribution and probability of receiving ACT with the SoC were based on data from an academic cancer center. The probability of receiving ACT with the prognostic test was estimated from a physician survey. Risk classification was based on the 5-year predicted NSCLC-related mortality. Treatment benefit with ACT was based on the prognostic score. Discounting at a 3% annual rate was applied to costs and

show abstract

Prognostic Factors and the Significance of Treatment After Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer

Cited by 61 publications

References 36 publications

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

Isolated brain metastasis as a late recurrence of completely resected non-small cell lung cancer

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About